Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster ...

Vladimir Tarasenko scored the go-ahead goal in the second period, Matt Boldy had a goal and an assist, and the Minnesota Wild twice benefited from replay reviews in a 5-2 ...

Bottle of Foundayo, a GLP-1 pill from Eli Lilly approved by the FDA to treat obesity Bottle of Foundayo, a GLP-1 pill from Eli Lilly approved by the FDA to treat obesityEli Lilly & Company Senior ...

Eli Lilly’s once-daily pill for weight loss got approval from U.S. drug regulators Wednesday. The all-clear sets up a battle with rival Novo Nordisk, which has been selling a pill version of its ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Food and Drug Administration has approved Foundayo, Eli Lilly’s new GLP-1 pill to treat ...

The US Food and Drug Administration on Wednesday approved a new obesity pill called Foundayo. Taken once daily, the pill is made by pharmaceutical company Eli Lilly, which also manufactures the ...

Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI than us … except for these guys,” he said. He ...

While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a crack in the company’s armor may be forming, according to at least one analyst.

With the success of GLP-1-based drugs, pharmaceutical companies are aggressively pursuing next-generation versions that could provide patients with more refined options for controlling diabetes and ...

Retatrutide, an experimental diabetes drug produced by Eli Lilly, helped some trial participants lose over 15% of their body weight, according to results of a new study released by the drug ...

With shares up 20% over the past 12 months, Eli Lilly appears to have come out on top in the battle to dominate the weight-loss drug market, with rival Novo Nordisk sinking 52% over the same period.

In a surprising move, Eli Lilly’s stock has been downgraded by HSBC analysts who argue that the heavily hyped weight-loss-drug market is due for a correction — and that the middle-class Americans who ...